REDWOOD
CITY, Calif., Oct. 26,
2023 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a
biotechnology company reimagining cell therapy through the
development of innovative immunotherapies for patients with cancer
and other incurable diseases, today announced that the management
team will participate in two upcoming investor conferences:
TD Cowen 7th Annual Fall Oncology Innovation Summit
(Virtual)
Fireside Chat: Friday,
November 3 at 12:30 p.m.
ET
Stifel 2023 Healthcare Conference, New York, NY (In Person)
Fireside Chat:
Wednesday, November 15 at
1:15 p.m. ET
A live webcast of these discussions will be accessible from
Arcellx's website at www.arcellx.com in the Investors section.
A replay of the webcasts will be archived and available for
30 days following the event.
About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage
biotechnology company reimagining cell therapy by engineering
innovative immunotherapies for patients with cancer and other
incurable diseases. Arcellx believes that cell therapies are one of
the forward pillars of medicine and Arcellx's mission is to advance
humanity by developing cell therapies that are safer, more
effective, and more broadly accessible. Arcellx's lead product
candidate, CART-ddBCMA, is being developed for the treatment of
relapsed or refractory multiple myeloma (rrMM) in a Phase 2 pivotal
trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and
Regenerative Medicine Advanced Therapy designations by the U.S.
Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T
therapy, ARC-SparX, through two clinical-stage programs: a Phase 1
study of ACLX-001 for rrMM, initiated in the second quarter of
2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia
and high-risk myelodysplastic syndrome, initiated in the fourth
quarter of 2022. For more information on Arcellx, please
visit www.arcellx.com. Follow Arcellx on X (formerly Twitter,
@arcellx) and LinkedIn.
Forward-looking Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. All statements in this
press release that are not purely historical are forward-looking
statements, including Arcellx's expectations regarding the timing
and outcomes of clinical trials for its product candidates and the
potential impact of its product candidates and platforms on
patients and cell therapy. The forward-looking statements contained
herein are based upon Arcellx's current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. These forward-looking statements are neither promises
nor guarantees and are subject to a variety of risks and
uncertainties, including risks that may be found in the section
entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on
Form 10-Q for the quarter ended June 30,
2023, filed with the Securities and Exchange Commission
(SEC) on August 14, 2023, and other
documents that Arcellx files from time to time with the SEC. These
forward-looking statements are made as of the date of this press
release, and Arcellx assumes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
Investors:
Myesha
Lacy
ir@arcellx.com
510-418-2412
Media:
Andrea Cohen Sam Brown Inc.
andreacohen@sambrown.com
917-209-7163
View original content to download
multimedia:https://www.prnewswire.com/news-releases/arcellx-to-participate-in-two-upcoming-investor-conferences-301969268.html
SOURCE Arcellx, Inc.